Dr. Andrew C. von Eschenbach, M.D., served as U.S. Commissioner of the Food and Drug Administration (FDA) from September 2005 to January 2009 where he championed an agenda to modernize the agency by process improvement of the regulatory pathway for drugs and medical devices and by fostering creative research. Dr. von Eschenbach joined the FDA after serving for four years as Director of the National Cancer Institute (NCI), National Institutes of Health. While at NCI, he supported the development of unprecedented programs in bioinformatics, large-scale genomics, nanotechnology, and biomarker science to enable the development of personalized cancer medicine. These programs were designed to enable the application of advanced technologies and the molecular sciences to specifically accelerate progress toward an aggressive goal of accelerating progress against cancer.

Dr. von Eschenbach is a nationally prominent surgeon recognized researcher and expert in prostate cancer, and was president-elect of the American Cancer Society when he was selected by the President to head the NCI. To date he is the only individual to serve as Director of the NCI and Commissioner of the FDA. Dr. von Eschenbach earned his medical degree from Georgetown University School of Medicine and a B.S. from St. Joseph’s University. He served as a Lt. Commander in the U.S. Navy Medical Corps.

Dr. von Eschenbach currently serves as President of Samaritan Health Initiatives, Inc, a consultant for the Center for Health Transformation and Adjunct Professor at the University of Texas MD Anderson Cancer Center.

**The Revolution in Biology and Molecular Medicine**

**When:** Friday, March 9, 2012  
**Where:** ASU Tempe Campus, Biodesign Institute Auditorium  
**Time:** 10:00 a.m. – 11:30 a.m.

Seminar sponsored by Complex Adaptive Systems Initiative (CASI) and The Biodesign Institute